LeonaBio (LONA) Enterprise Value (2019 - 2026)
LeonaBio (LONA) posted quarterly Enterprise Value of -$67.7 million for Q1 2026, down 84.56% year-over-year from -$438.4 million in Q1 2025, and up 23.38% quarter-over-quarter from -$88.3 million in Q4 2025.
LeonaBio (LONA) Enterprise Value (2019 - 2026) Analysis & Trends
LeonaBio (LONA) has reported Enterprise Value for 8 consecutive years, with -$67.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 84.56% year-over-year to -$67.7 million; the TTM figure through Mar 2026 stood at -$67.7 million (down 84.56% YoY), while the FY2025 annual figure was -$88.3 million, down 72.27% from the prior year.
- Enterprise Value climbed to -$67.7 million in Q1 2026 per LONA's latest filing, from -$88.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$25.2 million in Q3 2025 and bottomed at -$263.5 million in Q1 2022.
- Historically, Enterprise Value has averaged -$130.0 million across 5 years, with a median of -$122.1 million in 2024.
- Annual changes were most pronounced in 2025 — Enterprise Value surged 69.96% — and 2026, when it sank 84.56%.
- LeonaBio's Enterprise Value stood at -$200.3 million in 2022, then rose by 26.42% to -$147.4 million in 2023, then soared by 65.22% to -$51.3 million in 2024, then slumped by 72.27% to -$88.3 million in 2025, then advanced by 23.38% to -$67.7 million in 2026.
- Business Quant data shows LONA's Enterprise Value at -$67.7 million in Q1 2026, -$88.3 million in Q4 2025, and -$25.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | LeonaBio | 182.69 Mn | 131.62 Mn | - | -51.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -67.68 Mn |
| Dec 31, 2025 | -88.33 Mn |
| Sep 30, 2025 | -25.23 Mn |
| Jun 30, 2025 | -29.82 Mn |
| Mar 31, 2025 | -36.67 Mn |
| Dec 31, 2024 | -51.28 Mn |
| Sep 30, 2024 | -77.23 Mn |
| Jun 30, 2024 | -82.20 Mn |
| Mar 31, 2024 | -122.09 Mn |
| Dec 31, 2023 | -147.42 Mn |
| Sep 30, 2023 | -172.95 Mn |
| Jun 30, 2023 | -186.09 Mn |
| Mar 31, 2023 | -185.98 Mn |
| Dec 31, 2022 | -200.34 Mn |
| Sep 30, 2022 | -220.96 Mn |
| Jun 30, 2022 | -252.40 Mn |
| Mar 31, 2022 | -263.53 Mn |
| Dec 31, 2021 | -253.76 Mn |
| Sep 30, 2021 | -235.78 Mn |
| Jun 30, 2021 | -284.94 Mn |